Affimed N.V. (AFMD) Coverage Initiated by Analysts at SunTrust Banks, Inc.
SunTrust Banks, Inc. assumed coverage on shares of Affimed N.V. (NASDAQ:AFMD) in a research report released on Thursday, July 13th, Marketbeat Ratings reports. The firm issued a buy rating and a $7.00 target price on the biopharmaceutical company’s stock.
Other analysts also recently issued reports about the company. Oppenheimer Holdings, Inc. reissued a buy rating on shares of Affimed N.V. in a research note on Wednesday, March 22nd. Zacks Investment Research raised Affimed N.V. from a hold rating to a buy rating and set a $2.75 target price for the company in a report on Wednesday, April 19th. Jefferies Group LLC upped their target price on Affimed N.V. to $2.50 and gave the company a hold rating in a report on Wednesday, April 26th. Finally, ValuEngine raised Affimed N.V. from a strong sell rating to a sell rating in a report on Friday, June 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Affimed N.V. has an average rating of Hold and an average price target of $4.80.
Shares of Affimed N.V. (NASDAQ:AFMD) opened at 2.20 on Thursday. The firm’s market cap is $96.66 million. Affimed N.V. has a 12-month low of $1.65 and a 12-month high of $3.25. The firm’s 50-day moving average price is $2.22 and its 200 day moving average price is $2.23.
Affimed N.V. (NASDAQ:AFMD) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. The firm had revenue of $0.51 million during the quarter, compared to the consensus estimate of $1.31 million. Affimed N.V. had a negative return on equity of 73.85% and a negative net margin of 978.31%. The company’s quarterly revenue was down 75.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.24) earnings per share. On average, equities analysts expect that Affimed N.V. will post ($0.89) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Affimed N.V. (AFMD) Coverage Initiated by Analysts at SunTrust Banks, Inc.” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/08/affimed-n-v-afmd-earns-buy-rating-from-analysts-at-suntrust-banks-inc-updated-updated-updated.html.
Several institutional investors have recently bought and sold shares of AFMD. Creative Planning raised its position in Affimed N.V. by 7.7% in the second quarter. Creative Planning now owns 70,000 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 5,000 shares during the last quarter. Nationwide Fund Advisors raised its position in Affimed N.V. by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock worth $1,113,000 after buying an additional 479,007 shares during the last quarter. Tekla Capital Management LLC raised its position in Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock worth $3,232,000 after buying an additional 1,111,111 shares during the last quarter. NEA Management Company LLC bought a new position in Affimed N.V. during the first quarter worth approximately $8,944,000. Finally, Wellington Management Group LLP raised its position in Affimed N.V. by 30.8% in the first quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock worth $12,450,000 after buying an additional 1,274,852 shares during the last quarter. 42.41% of the stock is owned by hedge funds and other institutional investors.
Affimed N.V. Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Stock Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related stocks with our FREE daily email newsletter.